Search For
/
Stocks
Intraday Booster
Sector Booster
Stock Screener
Market Pulse
Screeners
More
Go Prime
My Plans
Privacy Policy
Contact
Refer & EarnScreenersMain
Stock Screener
Create Screener
Explore Screeners
Community ScreenersTrading Screeners
CandleSticks Screener
Top Gainers & Losers
Opening Range Breakout
Stock Screener AI
Stock Quality Scorecard
Overvalued StocksNewUndervalued StocksNewTechnical Screeners
NR4 Stocks
NR7 Stocks
Previous Day High Breakout
Previous Day Low Breakout
Previous Day Open Breakout
Bullish Crossover Stocks
Bearish Crossover Stocks
High Volume Shocker
VWAP Breakout Stocks
Range High Breakout
Range Low BreakoutMoreMarkets
Global Market Today
Global Indices
Indian Indices
NIfty TodaySmart Money
FII DII DataNew
FII Buying
NSE Insider Trading
SLB Stocks DataDerivatives
FnO Movements
NSE F&O Lot Size
Ban ListAnalysis & Calendars
Technical DashboardSector Booster
Sector AnalysisNew
Result Calendar
Economic Calendar
Windlas Biotech
Small Cap•1,154 Employees•IPO 2021
Current Price
₹725.35
-11.65 (-1.58%)Updated
Today's Range
717.5
₹725.35
737
52 Week Range
52W Low₹706.90
52W High₹1140.00
₹725.35
Downside2.61%
Upside57.17%
Price Chart
Compare with Peers
Historical Ratios
Track top 12 most important financial ratios
P/E Ratio: Price to Earnings - Most used valuation metric
Loading chart...
Analyzing Investment Quality
Processing 9 key metrics...
Key Metrics
Hover for details
Valuation
Market Cap
₹1,839.79 Cr
Market Cap
Total market value of companyP/E Ratio
27.33
P/E Ratio
Price to Earnings. Lower is generally better (<25 is good)P/B Ratio
3.57
P/B Ratio
Price to Book Value. <3 may indicate undervaluationEPS
₹31.79
EPS
Earnings Per Share. Higher and growing is positiveProfitability
ROE
6.55%
ROE
Return on Equity. >15% is good, >20% is excellentROCE
17.00%
ROCE
Return on Capital Employed. >15% is goodNet Margin
8.11%
Net Margin
Net profit as % of revenue. >10% is goodOperating Margin
-%
Operating Margin
Operating profit margin. >15% is goodGrowth
EPS Growth (5Y)
31.17%
EPS Growth (5Y)
5-year EPS growth. >15% is strongRevenue Growth (5Y)
18.24%
Revenue Growth (5Y)
5-year revenue growth. >10% is goodQtr Sales Growth
20.00%
Qtr Sales Growth
Quarter-over-quarter sales growthQtr Profit Growth
31.00%
Qtr Profit Growth
Quarter-over-quarter profit growthFinancial Health
Debt/Equity
0.06
Debt/Equity
Financial leverage. <1 is good, <0.5 is excellentBook Value
₹241.31
Book Value
Net asset value per shareDividend Yield
1.29%
Dividend Yield
Annual dividend as % of price. >2% is goodPromoter Holding
62.00%
Promoter Holding
Promoter stake. >50% shows confidenceGood
Average
Needs Attention
SWOT Analysis
Strengths
5 points- •Robust quarterly sales (20.00%) and profit (31.00%) growth demonstrate strong momentum.
- •Very low debt-to-equity ratio (0.06) ensures strong financial stability.
Weaknesses
5 points- •Modest Return on Equity (12.80%) suggests room for efficiency improvement.
- •ROCE (17.00%) lags peers like Sun Pharma, indicating efficiency gaps.
Opportunities
5 points- •Pharmaceuticals and Healthcare sector expansion offers significant market share growth.
- •Opportunity to explore new product lines, expanding market reach and revenue.
Threats
5 points- •Intense competition from larger, established players threatens market share.
- •Adverse regulatory changes in drug pricing or manufacturing standards pose risks.
Segment-wise Financial Analysis
Fetching Financials...
Fetching Balance Sheet...
Fetching Cash Flow...
Shareholding Pattern
Loading shareholding data...
Company Insider Trading Activity
No insider trading data available
Corporate Action
Company Announcements
Technical Analysis & Indicators
Standard pivot points - most widely used
Pivot Points (CLASSIC)
| Level | Price | Distance | % Change |
|---|---|---|---|
| R4 | ₹774.73 | +₹49.38 | +6.81% |
| R3 | ₹755.23 | +₹29.88 | +4.12% |
| R2 | ₹746.12 | +₹20.77 | +2.86% |
| R1 | ₹735.73 | +₹10.38 | +1.43% |
| PIVOT | ₹726.62 | 1.27 | 0.17% |
| CURRENT | ₹725.35 | - | - |
| S1 | ₹677.23 | -₹48.12 | -6.63% |
| S2 | ₹696.73 | -₹28.62 | -3.95% |
| S3 | ₹707.12 | -₹18.23 | -2.51% |
| S4 | ₹716.23 | -₹9.12 | -1.26% |
CPR Levels
Support
Resistance
S4
N/A
S3
N/A
S2
N/A
S1
N/A
| CPR |
BC: N/AP: N/ATC: N/A
R1
N/A
R2
N/A
R3
N/A
R4
N/A
LTP: N/A
PDH: N/A
PDL: N/A
● Market Sentiment
is trading CPR, indicating
● CPR Width
CPR is
● Opening Range
Day's range: ~
● Price Position
Trading Inside opening range
Delivery Volume Analysis & Trading Activity
Latest Volume-21.7% vs avg
0.20L
(12 Mar 2026)Delivery %+3.5% vs avg
59.6%
(12 Mar 2026)Avg Volume (20D)20-day average
0.26L
(12 Feb - 12 Mar)Avg Delivery %Trend ↑
56.1%
(12 Feb - 12 Mar)Delivery % indicates the percentage of traded volume that resulted in actual delivery. Higher delivery % (>50%) suggests genuine buying interest and stronger hands.
Peer Comparison & Industry Benchmarking
Quick Compare
Largest by Market Cap
Divis Laboratories Ltd
1.64L ₹ Cr
Best Profit Growth
Brooks Laboratories Ltd
498.00 %
Highest Dividend Yield
Divis Laboratories Ltd
0.49 %
Peer Comparison
| Company Name |
|---|
 Akums Drugs & Pharmaceuticals Ltd |
 Borosil Scientific Ltd |
 Brooks Laboratories Ltd |
 Dishman Carbogen Amcis Ltd |
 Divis Laboratories Ltd |
 |
 Innova Captab Ltd |
 Suven Life Sciences Ltd |
 Tarsons Products Ltd |
 Vimta Labs Ltd |
About
Windlas Biotech Ltd
Windlas Biotech Limited is a prominent contract development and manufacturing organization (CDMO) operating in the pharmaceutical industry, both domestically within India and on a global scale. Their core business revolves around providing comprehensive CDMO solutions to other pharmaceutical companies, encompassing the entire lifecycle from initial product development and securing necessary licenses to the large-scale commercial manufacturing of diverse pharmaceutical products.
The company specializes in the production of complex drugs and various dosage forms, demonstrating a high level of technical expertise and manufacturing capabilities. This expertise extends to a wide range of pharmaceutical products including tablets, capsules, pouches, sachets, and liquid bottles. Their manufacturing capabilities are not limited to simple formulations, they also handle more intricate formulations such as fixed dosage combinations, fixed dosage plus modified release combinations, customized generics, and specialized formats like chewable or dispersible tablets, and plain oral solid dosage forms.
Beyond its CDMO services, Windlas Biotech also has a significant presence in the manufacturing and trading of generic pharmaceutical products. This further diversifies their revenue streams and establishes them as a key player within the broader Indian and international pharmaceutical market. Their portfolio of generic products caters to a wide range of therapeutic needs, solidifying their position as a reliable supplier of affordable and accessible medications.
In addition to traditional pharmaceuticals, Windlas Biotech also engages in the production of nutraceutical supplement products, highlighting their adaptability and expansion into related health and wellness markets. This diversification strategy allows the company to tap into growing consumer demand for health-enhancing supplements, further broadening their product range and market reach. This strategic diversification demonstrates their commitment to growth and innovation within the broader healthcare industry.
Established in 2001 and headquartered in Gurugram, India, Windlas Biotech Limited has built a strong reputation based on its expertise in complex pharmaceutical manufacturing, comprehensive CDMO services, and diverse product portfolio. This combination of factors positions the company for continued success and growth in the dynamic and ever-evolving global pharmaceutical landscape.
COMPANY FACTS - WINDLAS
Registered Address
705-706, Vatika Professional Point, Sector-66 Golf Course Extension Road
Gurgaon
HARYANA
IN
Tel: 911242821030
Website:https://windlas.com/
Investor Relations:https://windlas.com/investor-information/fact-sheet-2/
Company Details
Group: Pharmaceuticals, Biotechnology & Life Sciences
Sector: Health Care
Industry: Life Sciences Tools & Services
Exchange: NATIONAL STOCK EXCHANGE OF INDIA
Employees: 1,154
IPO Date: 16/08/2021
Investor Questions Answered
Windlas Biotech Ltd (WINDLAS) Stock FAQs
Get answers to the most common questions about Windlas Biotech Ltd stock price, fundamentals, financial metrics, and investment analysis
The current share price of Windlas Biotech Ltd (WINDLAS) is ₹725.35. Today, the stock has declined by ₹11.65 (1.58%), trading in a range of ₹717.5 to ₹737. The stock opened at ₹736.2 with a trading volume of 25,031 shares.
Windlas Biotech Ltd can be considered for long-term investment based on several factors. The company has a market capitalization of ₹1,839.79 crores, P/E ratio of 27.33, ROE of 6.55%, and ROCE of 17.00%. The dividend yield stands at 1.29%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
The 52-week high price of Windlas Biotech Ltd (WINDLAS) is ₹1,140, while the 52-week low is ₹706.9. Currently trading at ₹725.35, the stock is 4.3% away from its 52-week low and 36.4% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
Whether to buy Windlas Biotech Ltd stock at ₹725.35 depends on multiple factors. The stock is currently trading with a P/E ratio of 27.33 and P/B ratio of N/A. Today's performance shows a loss of 1.58%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
Windlas Biotech Ltd offers a dividend yield of 1.29%, which means for every ₹100 invested at the current price of ₹725.35, you can expect to receive approximately ₹1.29 annually as dividends. The face value of the stock is ₹5.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
Windlas Biotech Ltd's key financial metrics include: P/E Ratio: 27.33, P/B Ratio: N/A, ROE: 6.55%, ROCE: 17.00%, Dividend Yield: 1.29%, EPS: ₹31.79, Book Value: ₹241.31, Debt-to-Equity: 0.06, and Current Ratio: N/A. The company's market cap stands at ₹1,839.79 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
Windlas Biotech Ltd stock opened at ₹736.2 and is currently trading at ₹725.35, showing a decline of ₹11.65 (1.58%). The intraday high is ₹737 and low is ₹717.5. The trading volume stands at 25,031 shares, indicating moderate market participation today.
Windlas Biotech Ltd has a Price-to-Earnings (P/E) ratio of 27.33, which means investors are willing to pay ₹27.33 for every ₹1 of earnings. With an EPS of ₹31.79, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
Windlas Biotech Ltd has a market capitalization of ₹1,839.79 crores, making it a small-cap company. Market cap is calculated by multiplying the current stock price (₹725.35) by the total number of outstanding shares. This metric helps investors understand the company's size, stability, and investment risk profile.
Windlas Biotech Ltd has a book value of ₹241.31 per share and a Price-to-Book (P/B) ratio of N/A. The current market price is ₹725.35, which is 200.6% above the book value. A P/B ratio below 1 may indicate undervaluation or asset quality concerns.
Windlas Biotech Ltd has a Return on Equity (ROE) of 6.55% and Return on Capital Employed (ROCE) of 17.00%. ROE measures how efficiently the company generates profits from shareholders' equity, while ROCE indicates how well the company uses its capital to generate profits. These returns may need improvement for better profitability. Higher percentages generally indicate better financial performance.
Windlas Biotech Ltd operates in the diversified sector and belongs to the general industry. The company competes with other players in this space and its performance is influenced by sector-specific trends, regulatory changes, and market dynamics. Understanding the sector helps investors assess growth potential, cyclical patterns, and industry-specific risks that may impact the stock's performance.
Windlas Biotech Ltd has a debt-to-equity ratio of 0.06, which measures the company's financial leverage by comparing total debt to shareholders' equity. A low ratio suggests conservative financing with minimal debt. Lower ratios generally indicate lower financial risk, but optimal levels vary by industry.
Windlas Biotech Ltd has an Earnings Per Share (EPS) of ₹31.79, which represents the company's profit allocated to each outstanding share. With a current stock price of ₹725.35 and P/E ratio of 27.33, investors are paying 27.33 times the annual earnings per share. This moderate EPS suggests decent earnings generation. Track EPS growth over quarters to assess earnings momentum.
Windlas Biotech Ltd has reported a sales growth of N/A% and profit growth of N/A%. The company may be facing growth challenges or operating in a mature market. Consistent growth over multiple quarters is a positive indicator for long-term investors. Compare these growth rates with industry peers for better perspective.
Windlas Biotech Ltd has a current ratio of N/A, which measures the company's ability to pay short-term obligations with current assets. A ratio below 1 may indicate potential liquidity concerns. This metric is crucial for assessing the company's working capital management and financial safety.
To analyze Windlas Biotech Ltd stock, consider: 1) Fundamental Analysis - Review P/E (27.33), ROE (6.55%), debt-to-equity (0.06), and growth rates. 2) Technical Analysis - Check 52-week range (₹706.90 - ₹1140.00), moving averages, and chart patterns. 3) Valuation - Compare current price (₹725.35) with book value (₹241.31) and industry peers. 4) Financial Health - Assess current ratio (N/A) and cash flows. 5) Growth Prospects - Evaluate sales growth (N/A%) and profit growth (N/A%). Always diversify and consult a financial advisor.
The face value (or par value) of Windlas Biotech Ltd share is ₹5.00. Face value is the nominal value of a share as stated in the company's charter and is used for accounting purposes and calculating dividends. The current market price of ₹725.35 is 14407x the face value. Face value remains constant unless the company undergoes a stock split or bonus issue, while market price fluctuates based on demand and supply.
Investing in Windlas Biotech Ltd carries several risks: 1) Market Risk - Stock price volatility (52-week range: ₹706.90 - ₹1140.00). 2) Business Risk - Industry-specific challenges in the sector. 3) Financial Risk - Debt-to-equity ratio of 0.06 indicates leverage. 4) Liquidity Risk - Based on trading volume of 25,031 shares. 5) Valuation Risk - P/E of 27.33 may indicate over/undervaluation. 6) Economic Risk - Macroeconomic factors affecting the industry. Diversify your portfolio and invest only what you can afford to lose.
Windlas Biotech Ltd operates in the industry with key metrics: P/E ratio of 27.33, ROE of 6.55%, market cap of ₹1,839.79 crores, and dividend yield of 1.29%. To make an informed comparison, analyze these metrics against industry peers considering factors like revenue growth (N/A%), profit margins, debt levels (D/E: 0.06), and market position. Use our peer comparison tool on this page to see detailed side-by-side analysis with competitors.
Target prices for Windlas Biotech Ltd vary among analysts and depend on multiple factors including earnings projections, industry trends, and market conditions. The stock is currently trading at ₹725.35, with a 52-week range of ₹706.90 to ₹1140.00. Based on fundamentals like P/E (27.33), ROE (6.55%), and growth rates, analysts may have different target prices. Always refer to recent research reports from reputed brokerages and make decisions based on your own analysis and risk appetite.
Consider selling Windlas Biotech Ltd stock when: 1) Target Price Achieved - If the stock reaches your predetermined target from current ₹725.35. 2) Fundamental Deterioration - Declining ROE (currently 6.55%), increasing debt (D/E: 0.06), or falling growth rates. 3) Better Opportunities - Finding stocks with superior risk-reward ratios. 4) Portfolio Rebalancing - When the stock becomes overweight in your portfolio. 5) Changed Investment Thesis - If reasons for buying no longer hold. 6) Stop Loss - If price falls below your risk threshold. Always base decisions on thorough analysis rather than emotions.
Tax implications for Windlas Biotech Ltd stock investments: 1) Short-term Capital Gains (STCG) - If sold within 1 year, gains taxed at 15% plus cess. 2) Long-term Capital Gains (LTCG) - If held over 1 year, gains above ₹1 lakh taxed at 10% without indexation. 3) Dividend Income - Dividends (current yield: 1.29%) are taxable as per your income tax slab. 4) Securities Transaction Tax (STT) - Applicable on both buy and sell transactions. 5) Intraday Trading - Treated as speculative income, taxed as per slab. Tax laws change periodically, so consult a tax advisor for personalized guidance and latest regulations.
Menu